Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-16
    E.g., 2018-08-16

Articles

19358 items
12:00 AM, Sep 07, 1993  |  BioCentury | Finance

Lidak, Dorfman lock horns

Katz said the offering Dorfman referred to was a routine update of a shelf registration relating to a private placement completed in February 1992. Under the terms of the placement, the shares and shares underlying...
12:00 AM, Sep 07, 1993  |  BioCentury | Product Development

Cellegy's cross-over skin treatment

In the old model, an insult to the skin passed through the outer dead layer of cells and elicited a response in the dermis, which then was reflected on the surface. In fact, many skin...
12:00 AM, Sep 07, 1993  |  BioCentury | Politics, Policy & Law

Pryor, Cohen drop jawbone on Betaseron price on

WASHINGTON - Senators David Pryor and William Cohen have abandoned, at least for now, their campaign to test the "reasonableness" of the pricing of Betaseron, Chiron Corp.'s new drug for multiple sclerosis. In an Aug. 30th...
12:00 AM, Sep 07, 1993  |  BioCentury | Strategy

Surging Activase sustaining its clinical impact

Activase's market share began rising in April, after the 41,021-patient GUSTO study results indicated that patients given accelerated treatment with tPA plus heparin had 6.3 percent mortality compared with 7.3 percent mortality in patients treated...
12:00 AM, Sep 07, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Cel-Sci Corp. (CELI) Douglas Fahoury of Cohig & Associates initiated coverage with a "buy." Fahoury said early trials in Florida of CELI's Multikine cytokine cocktail showed promising results in head and neck cancer patients....
12:00 AM, Sep 07, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Ethical Holdings plc (ETHCY) David Steinberg of Volpe, Welty & Co. said that the purchase by Ethical Holdings plc of Gacell Holdings, a Swedish drug delivery company, helps move ETHCY out of a large peer...
12:00 AM, Sep 07, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Regeneron Pharmaceuticals Inc. (REGN) Montgomery Securities analyst Brandon Fradd initiated coverage with a "buy." Fradd said the current fair value of the stock is $18-$20. He said he expects presentation in September of Phase II...
12:00 AM, Sep 07, 1993  |  BioCentury | Strategy

Special back-to-school edition

Commentary  At least half the industry returns to work today from vacation. We may exaggerate somewhat, but nevertheless we hope the late summer break taken by many biotech investors and executives results in renewed energy for...
12:00 AM, Aug 30, 1993  |  BioCentury | Politics, Policy & Law

focus

WASHINGTON - Declaring that increasing competition has caused the U.S. leadership in biotechnology to diminish, the Clinton administration last week sent to Congress details of a $4.3 billion "Federal Biotechnology Research Initiative" whose goal is...
12:00 AM, Aug 30, 1993  |  BioCentury | Finance

Making a virtue of low market cap

Making a virtue of low market cap Whether it was intended or not, Anergen Inc.'s failure to gorge itself at the 1991-92 funding trough has enabled it to offer its first corporate partner a sizeable...

Pages